Noora (vaccine)
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular

Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. (lit. White Cypress Plasma Treatment) in Iran.[1][2]

Medical uses

It requires three doses given by intramuscular injection on days 0, 21 and 35.[3]

Pharmacology

Noora is a recombinant RBD protein subunit vaccine.[3]

Manufacturing

Up to 8 December 2021, 5 millions doses have been produced.[4]

Clinical trials

Clinical trials of Noora
Phase Registration number Start Number of participants Age of participants Ref
Total Vaccine Placebo
I IRCT20210620051639N1 25 June 2021 70 30 (80 µg)

30 (120 µg)

 10 (placebo) 18–50 years [3]
II IRCT20210620051639N2 10 October 2021 300 240 60 18–40 years [5]
III IRCT20210620051639N3 23 December 2021 10000 >18 years [6]

See also

References

  1. ↑ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
  2. ↑ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. Retrieved 30 August 2021.
  3. 1 2 3 "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
  4. ↑ "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim". خبرگزاری تسنیم | Tasnim (in Persian). Retrieved 8 December 2021.
  5. ↑ "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population". en.irct.ir. Retrieved 27 November 2021.
  6. ↑ "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". en.irct.ir. Retrieved 23 December 2021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.